Financial Performance - The company's revenue for Q1 2024 was CNY 436,441,198.76, representing a 5.78% increase compared to CNY 412,587,989.38 in the same period last year[5] - Net profit attributable to shareholders decreased by 95.00% to CNY 1,071,720.66 from CNY 21,413,081.32 year-on-year[5] - Basic and diluted earnings per share dropped by 94.95% to CNY 0.0027 from CNY 0.0535 year-on-year[5] - Net profit for Q1 2024 was CNY -264,826.54, a significant decrease from CNY 15,591,014.71 in Q1 2023[22] - Total operating revenue for Q1 2024 was CNY 436,441,198.76, an increase of 5.8% compared to CNY 412,587,989.38 in Q1 2023[21] - Total operating costs rose to CNY 410,500,506.73, up 11.2% from CNY 368,985,556.77 in the previous year[21] Cash Flow - The net cash flow from operating activities was negative at CNY -38,737,542.37, a decline of 162.75% compared to CNY 61,732,450.68 in the previous year[5] - Cash received from sales of goods and services was 420,445,869.80, down from 651,926,466.31 in the prior period, reflecting a decrease of approximately 35.4%[24] - Cash paid to employees decreased to 69,042,247.42 from 167,028,894.44, a reduction of about 58.7%[24] - Cash inflow from investment activities totaled 50,195,671.23, compared to 8,007,257.47 in the prior period, indicating a substantial increase[25] - Cash outflow for investment activities was 67,653,847.10, compared to 24,740,279.64 in the previous period, showing an increase of approximately 172%[25] - The net cash flow from financing activities was negative at CNY -14,143,681.47, a decline from CNY 11,309,552.97 in the previous period[25] - Cash inflow from financing activities decreased to 5,495,100.00 from 20,900,000.00, a decline of about 73.7%[25] - The company received 3,000,000.00 from minority shareholders, an increase from 1,000,000.00 in the previous period[25] - The impact of exchange rate changes on cash and cash equivalents was -165,527.41, contrasting with a positive impact of 32,217.55 in the prior period[25] Assets and Liabilities - Total assets decreased by 3.08% to CNY 2,894,810,431.30 from CNY 2,986,860,553.79 at the end of the previous year[5] - The company's total liabilities decreased to CNY 917,043,600.56 from CNY 1,006,695,890.02 year-over-year[20] - The total equity attributable to shareholders of the parent company was CNY 1,776,254,991.66, slightly down from CNY 1,780,316,277.50 in the previous year[20] - Total current assets decreased from 2,326,522,955.04 to 2,240,279,877.17, a reduction of approximately 3.7%[18] - Cash and cash equivalents decreased from 861,200,747.83 to 789,752,449.46, a decline of about 8.3%[17] - Accounts receivable increased from 1,010,473,055.69 to 1,032,983,314.49, an increase of approximately 2.3%[17] - Inventory decreased from 367,710,046.84 to 334,039,996.24, a reduction of about 9.2%[18] - Non-current assets decreased from 660,337,598.75 to 654,530,554.13, a reduction of about 0.9%[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 32,038[13] - Shanghai Lanwei Investment Co., Ltd. holds 37.34% of shares, totaling 149,554,017 shares[13] - The total number of restricted shares at the end of the period is 220,277,568, with no shares released during the current period[15] - The company repurchased shares, resulting in a 50.05% increase in treasury stock to CNY 15,388,150.58 from CNY 10,255,144.08[10] Research and Development - Research and development expenses were CNY 9,985,811.02, a decrease from CNY 10,753,900.80 in the same period last year[21] - The company has no new product or technology developments reported in the current quarter[14] Other Financial Metrics - The weighted average return on equity fell to 0.06% from 1.03% year-on-year, a decrease of 0.97%[5] - The company reported a significant decline in other income, which fell by 88.14% to CNY 1,936,000.12 from CNY 16,326,865.98 in the same period last year[11] - The cash flow from financing activities was negative at CNY -14,143,681.47, a decrease of 225.06% compared to CNY 11,309,552.97 in the previous year[11] - The company reported a credit impairment loss of CNY -23,167,116.60, an improvement from CNY -35,517,924.09 in Q1 2023[21] - Cash flow details for Q1 2024 are yet to be disclosed in the report[23] - The company continues to focus on expanding its market presence and enhancing its service offerings[23]
兰卫医学(301060) - 2024 Q1 - 季度财报